More about

Lymphoma

News
December 11, 2021
3 min read
Save

EFS improvement with axi-cel CAR-T a ‘breakthrough’ in second-line treatment of DLBCL

EFS improvement with axi-cel CAR-T a ‘breakthrough’ in second-line treatment of DLBCL

Second-line therapy with axicabtagene ciloleucel conferred a fourfold increase in EFS compared with standard-of-care treatment for diffuse large B-cell lymphoma, according to results of a randomized phase 3 study.

News
December 03, 2021
1 min read
Save

FDA approves Rituxan plus chemotherapy for pediatric lymphoma, leukemia

The FDA approved rituximab in combination with chemotherapy for several pediatric cancer indications.

News
December 02, 2021
7 min read
Save

Award recipient’s advice to early-career oncologists: ‘Do not be bashful,’ ask questions

Award recipient’s advice to early-career oncologists: ‘Do not be bashful,’ ask questions

The William L. McGuire Lecture Award will be presented to Olufunmilayo Olopade, MD, FAACR, at San Antonio Breast Cancer Symposium this month.

News
December 01, 2021
1 min read
Save

FDA grants orphan drug designation to nanatinostat and valganciclovir for lymphoma subset

The FDA granted orphan drug designation to nanatinostat and valganciclovir for treatment of Epstein Barr virus-positive diffuse large B-cell lymphoma not otherwise specified.

News
November 09, 2021
3 min read
Save

Targeted therapies transforming treatment of indolent non-Hodgkin lymphoma

Targeted therapies transforming treatment of indolent non-Hodgkin lymphoma

Targeted therapies have rapidly changed the treatment landscape of indolent non-Hodgkin lymphoma, a heterogenous group of diseases for which individualized care is crucial, according to a speaker at Chemotherapy Foundation Symposium.

News
November 08, 2021
1 min read
Save

FDA grants fast track designation to EZM0414 for diffuse large B-cell lymphoma

FDA grants fast track designation to EZM0414 for diffuse large B-cell lymphoma

The FDA granted fast track designation to EZM0414 for treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.

News
November 05, 2021
4 min read
Save

Experts discuss management of cancer therapies in the era of COVID-19

Experts discuss management of cancer therapies in the era of COVID-19

Management of cancer therapies in the era of COVID-19 infection and vaccination requires careful consideration of both disease and patient characteristics, according to members of a crossfire panel at Chemotherapy Foundation Symposium.

News
November 04, 2021
2 min read
Save

CAR T-cell therapy linked to cardiovascular, pulmonary adverse effects

CAR T-cell therapy linked to cardiovascular, pulmonary adverse effects

Chimeric antigen receptor T-cell therapy appeared associated with various cardiovascular and pulmonary adverse events, according to results of a retrospective pharmacovigilance study.

News
November 01, 2021
1 min read
Save

FDA grants priority review to parsaclisib for two lymphoma indications

FDA grants priority review to parsaclisib for two lymphoma indications

The FDA granted priority review to parsaclisib for two lymphoma indications.

News
October 29, 2021
1 min read
Save

ASH announces new executive committee members

ASH announces new executive committee members

Three individuals have been elected to American Society of Hematology’s executive committee.

View more